Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provenance Biopharmaceuticals, a biotechnology company, has signed a licensing agreement with Merck Serono for DI-Leu16-IL2, a potential anticancer therapeutic.
Subscribe to our email newsletter
Under this agreement, Merck Serono, which is the division for prescription pharmaceuticals of the German pharmaceutical and chemical group Merck KGaA, has granted exclusive worldwide rights to Provenance to develop and commercialize DI-Leu16-IL2.
This protein therapeutic is currently being tested in an investigator sponsored clinical trial in patients with non-Hodgkin’s lymphoma at the City of Hope National Medical Center in Duarte, California.
Under terms of the DI-Leu16-IL2 license agreement, Merck Serono will receive an upfront payment, various development and commercial milestones and royalties on sales. Provenance will be responsible for the clinical development and commercialization.